PetVivo Inc.
(PETV)
undefined
undefined%
At close: undefined
0.77
75.00%
Pre-market Sep 03, 2024, 09:30 AM EDT
Company Description
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals.
Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.
The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications.
PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PetVivo Inc.
| Country | United States |
| IPO Date | Sep 8, 2014 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 20 |
| CEO | John Lai |
Contact Details
Address: 5251 Edina Industrial Boulevard Minneapolis, Minnesota United States | |
| Website | https://www.petvivo.com |
Stock Details
| Ticker Symbol | PETV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001512922 |
| CUSIP Number | 716817408 |
| ISIN Number | US7168174081 |
| Employer ID | 99-0363559 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| John Lai | Chief Executive Officer, President & Director |
| Garry N. Lowenthal | Chief Financial Officer |
| Randall A. Meyer | Chief Operating Officer |
| April Boyce | Vice President of Marketing |
| Bryan Monninger | Vice President of Sales |
| Gary DeMel | Executive Vice President of Business Development |
| John F. Dolan | General Counsel, Chief Business Development Officer & Secretary |
| Randy Wenthold | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 29, 2024 | PRER14C | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 18, 2024 | 4/A | [Amend] Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |